Development of a Risk Prediction Score for Occult Cancer in Patients With VTE


Por: Jara-Palomares, L, Otero, R, Jimenez, D, Carrier, M, Tzoran, I, Brenner, B, Margeli, M, Praena-Fernandez, JM, Grandone, E and Monreal, M

Publicada: 1 mar 2017
Resumen:
BACKGROUND: The benefits of a diagnostic workup for occult cancer in patients with VTE are controversial. Our aim was to provide and validate a risk score for occult cancer in patients with VTE. METHODS: We designed a nested case-control study in a cohort of patients with VTE included in the RIETE (Registro Informatizado Enfermedad TromboEmbolica) registry from 2001 to 2014. Cases included cancer detected beyond the first 30 days and up to 24 months after VTE. Control subjects were defined as patients with VTE with no cancer in the same period. RESULTS: Of 5,863 eligible patients, 444 (7.6%; 95% CI, 6.8%-8.2%) were diagnosed with occult cancer. On multivariable analysis, variables selected were male sex, age > 70 years, chronic lung disease, anemia, elevated platelet count, prior VTE, and recent surgery. We built a risk score assigning points to each variable. Internal validity was confirmed using bootstrap analysis. The proportion of patients with cancer who scored <= 2 points was 5.8% (241 of 4,150) and that proportion in those who scored >= 3 points was 12% (203 of 1,713). We also identified scores divided by sex and age subgroups. CONCLUSIONS: This is the first risk score that has identified patients with VTE who are at increased risk for occult cancer. Our score needs to be externally validated.

Filiaciones:
Jara-Palomares, L:
 Hosp Virgen del Rocio, Med Surg Unit Resp Dis, Seville, Spain

 Ctr Invest Biomed Red Enfermedades Resp CIBERES, Inst Biomed Sevilla IBiS, Seville, Spain

Otero, R:
 Hosp Virgen del Rocio, Med Surg Unit Resp Dis, Seville, Spain

 Ctr Invest Biomed Red Enfermedades Resp CIBERES, Inst Biomed Sevilla IBiS, Seville, Spain

Jimenez, D:
 Hosp Ramon & Cajal, IRYCIS, Resp Dept, Madrid, Spain

Carrier, M:
 Univ Ottawa, Dept Med, Div Hematol, Thrombosis Program, Ottawa, ON, Canada

Tzoran, I:
 Rambam Med Ctr, Dept Hematol & Bone Marrow Transplantat, Thrombosis & Hemostasis Unit, Haifa, Israel

Brenner, B:
 Rambam Med Ctr, Dept Hematol & Bone Marrow Transplantat, Thrombosis & Hemostasis Unit, Haifa, Israel

:
 Hosp Badalona Germans Trias & Pujol, Dept Med Oncol, Barcelona, Spain

Praena-Fernandez, JM:
 Hosp Virgen del Rocio, Andalusian Publ Fdn Hlth Res Management, Stat Methodol & Res Evaluat Unit, Seville, Spain

Grandone, E:
 Casa Sollievo Sofferenza, Atherosclerosis & Thrombosis Unit, Foggia, Italy

:
 Hosp Badalona Germans Trias & Pujol, Dept Internal Med, Barcelona, Spain

Univ Catolica Murcia, Guadalupe, Spain.
ISSN: 00123692





Chest
Editorial
Elsevier Inc., RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS, Estados Unidos America
Tipo de documento: Article
Volumen: 151 Número: 3
Páginas: 564-571
WOS Id: 000397166400016
ID de PubMed: 27815153

MÉTRICAS